11/19/2015 | PP | Threshold plans to conduct $50 million at-the-market offering of stock
|
2/12/2015 | PP | Threshold Pharmaceuticals prices $30.05 million public stock sale
|
8/1/2014 | PP | Threshold Pharmaceuticals conducts $30 million at-the-market offering
|
1/20/2012 | PP | Threshold lifts at market issuance sales agreement to $17.58 million
|
6/10/2011 | CVPF | Threshold files $50 million shelf covering stock, debt and preferreds
|
3/11/2011 | PP | Threshold arranges $30.06 million registered direct offering of units
|
9/30/2010 | CVPF | Threshold files $50 million shelf covering stock, debt, preferreds
|
9/30/2009 | PP | New Issue: Threshold Pharmaceuticals plans $35 million private placement of units
|
9/30/2009 | PP | Market Commentary: Threshold to issue units; Rockwell Medical aims for $22 million; RegeneRx plans unit placement
|
7/10/2008 | PP | New Issue: Threshold Pharmaceuticals to sell $18.3 million of shares in private placement
|
9/14/2006 | BT | Market Commentary: Threshold, Discovery Labs gain on widespread deal speculation; Curis better; Genzyme gains 3%
|
8/9/2006 | BT | Threshold to reduce cash burn by cutting staff, refocusing R&D; board approves shareholder rights plan
|
8/8/2006 | BT | Threshold completes enrollment in pivotal phase 3 and phase 2 trials of glufosfamide in pancreatic cancer
|
7/17/2006 | BT | Market Commentary: Threshold plunges over 51%; Genitope firms; Vivus dives; Progenics weak; Alnylam off
|
7/17/2006 | BT | Threshold to stop TH-070 development
|
6/1/2006 | BT | Threshold: Safety monitoring board recommends glufosfamide trial continue to completion
|
5/16/2006 | BT | Market Commentary: Neurocrine, DOV dive; Novavax, Generex dive amid noise of exits; Adventrx slips modestly on deal
|
5/15/2006 | BT | Market Commentary: BioMimetic goes south; Sirna off on new deal; Cambridge rockets on buyout; Threshold extends fall
|
5/11/2006 | BT | Threshold's TH-070 program put on hold by FDA
|
4/5/2006 | BT | Threshold completes enrollment in phase 3 study of TH-070 for benign prostatic hyperplasia
|
3/20/2006 | BT | Threshold Pharmaceuticals completes enrollment in phase 2 hyperplasia study
|
1/11/2006 | BT | Threshold says phase 1 trial of glufosfamide with gemcitabine to treat pancreatic cancer yields positive results
|
10/12/2005 | BT | Market Commentary: Vical falls 20% on PIPEs deal; Threshold, Dynavax off on stock sales; Pharma Product higher
|
10/12/2005 | BT | New Issue: Threshold prices $65.375 million follow-on offering of 6.25 million shares at $10.46
|
10/10/2005 | BT | Market Commentary: Holiday makes for thin market; Gilead, niche flu drug names go higher; Human Genome lower yet
|
10/7/2005 | BT | Market Commentary: CoTherix off on follow-on deal; Human Genome slide unabated; Cytogen higher; flu names soar
|
9/28/2005 | BT | Market Commentary: Panacos, SkyePharma add to deal slate; Incyte, Endo drop on news; Electro-Optic rejigs talk, syndicate
|
9/27/2005 | BT | Threshold Pharmaceuticals to sell 6.25 million shares in follow-on offering
|